Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Open, Multicenter, Prospective, Phase II Clinical Trial of Doxorubicin vs. Trabectedin Plus Doxorubicin in the First Line Treatment of Patients With Advanced Non Operable and/or Metastatic Soft Tissue Sarcomas

NCT01104298 is registered in ClinicalTrials.gov with Grupo Espanol de Investigacion en Sarcomas as lead sponsor.

NCT NCT01104298
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01104298 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Open, Multicenter, Prospective, Phase II Clinical Trial of Doxorubicin vs. Trabectedin Plus Doxorubicin in the First Line Treatment of Patients With Advanced Non Operable and/or Metastatic Soft Tissue Sarcomas
Lead sponsor
Grupo Espanol de Investigacion en Sarcomas
Phase
Phase 2
Overall status
Terminated
Start date
November 30, 2009
Completion date
May 31, 2014
Enrollment
115 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

sarcoma